

## **Psoriatic Arthritis - Epidemiology Forecast - 2032**

Market Report | 2022-09-01 | 141 pages | DelveInsight

### **AVAILABLE LICENSES:**

- Single User Price \$4750.00
- Site License Price \$9500.00
- Enterprise Price \$14250.00

### **Report description:**

DelveInsight's 'Psoriatic Arthritis (PsA) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of psoriatic arthritis (PsA) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Psoriatic Arthritis (PsA): Disease Understanding

Psoriatic Arthritis (PsA) Overview

Psoriatic arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin and nail disease characterized by red, scaly rashes and thick pitted fingernails. Psoriatic arthritis (PsA) resembles rheumatoid arthritis (RA) in symptoms characterized by joint inflammation. However, psoriatic arthritis (PsA) affects fewer joints than RA and does not produce the typical RA antibodies.

In 1956, Wright described arthritis associated with psoriasis. However, it was not until 1973 that Moll and Wright defined the various clinical phenotypes, including axial PsA, symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis, and arthritis mutilans. The following year, these authors introduced the concept of spondyloarthritis, a cluster of diseases with shared clinical and immunogenetic features. Despite these advances, the immunopathogenesis of psoriatic arthritis (PsA) is poorly understood, awaiting a more detailed understanding of immune networks and the inflammatory response.

The etiology and pathogenesis of psoriatic arthritis (PsA) involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33-50% of PsA patients have at least one first-degree relative with psoriasis or psoriatic arthritis (PsA). Genes associated with psoriatic arthritis (PsA) include those in the HLA region involved in antigen presentation and immune recognition and non-HLA genes involved in immune activation and inflammation, including intracellular signaling, cytokine expression, and signaling T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma induces psoriatic skin lesions flares, known as the Koebner phenomenon. Evidence suggests that joint trauma may cause a flare of arthritis, referred to as the "internal" or "deep" Koebner phenomenon.

Psoriatic arthritis (PsA) shares some clinical features with other inflammatory arthritides, including RA, reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnosis. Unlike psoriatic arthritis (PsA), RA is symmetrical and generally spares the DIP joints. AS has an earlier onset age than psoriatic arthritis (PsA), and sacroiliac involvement is usually symmetric rather than asymmetric.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Psoriatic arthritis (PsA) may range from mild to severe, and its treatment is crucial despite the severity. If left untreated, psoriatic arthritis (PsA) can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating psoriatic arthritis (PsA) may also help reduce inflammation that could lead to other comorbidities. However, no cure for psoriatic arthritis (PsA) exists, so treatment goals are to slow disease progression, improve QoL, lessen pain, and preserve the range of motion. In most PsA patients, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs, if a patient does not respond adequately.

#### Epidemiology

Psoriatic arthritis (PsA) epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

#### Key Findings

The disease epidemiology covered in the report provides historical and forecasted psoriatic arthritis (PsA) epidemiology segmented as the prevalent cases of psoriatic arthritis (PsA), diagnosed cases of psoriatic arthritis (PsA), gender-specific cases of psoriatic arthritis (PsA), age-specific cases of psoriatic arthritis (PsA) and severity-specific cases of psoriatic arthritis (PsA). The report includes the prevalent psoriatic arthritis (PsA) scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

#### Country-wise psoriatic arthritis (PsA) Epidemiology

The epidemiology segment also provides psoriatic arthritis (PsA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent patient population of psoriatic arthritis (PsA) in the 7MM countries was close to 1.5 million in 2021.

As per the estimates, the US had the highest total patient population of psoriatic arthritis (PsA) in 2021. Among the EU5 countries, Spain had the highest total prevalent patient population of psoriatic arthritis (PsA), with more than 200,000 cases, followed by Italy in 2021. On the other hand, France had the lowest total prevalent patient population of psoriatic arthritis (PsA), close to 53,000 cases in 2021.

#### Scope of the Report

- Psoriatic arthritis (PsA) report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
- Psoriatic arthritis (PsA) epidemiology report and model provide an overview of the risk factors and global trends of psoriatic arthritis (PsA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides insight into the historical and forecasted patient pool of psoriatic arthritis (PsA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
- The report helps recognize the growth opportunities in the 7MM concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of psoriatic arthritis (PsA).
- The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by prevalent cases of psoriatic arthritis (PsA) in the 7MM.
- The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by diagnosed cases of psoriatic arthritis (PsA) in the 7MM.
- The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by age-specific cases of psoriatic arthritis (PsA) in the 7MM.
- The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by gender-based cases of psoriatic arthritis (PsA) in the 7MM.
- The report segments psoriatic arthritis (PsA) epidemiology by severity-specific cases of psoriatic arthritis (PsA) in the 7MM.

#### Report Highlights

- 11-year forecast of psoriatic arthritis (PsA) epidemiology
- 7MM coverage

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Prevalent cases of psoriatic arthritis (PsA)
- Diagnosed cases of psoriatic arthritis (PsA)
- Age-specific cases of psoriatic arthritis (PsA)
- Gender-specific cases of psoriatic arthritis (PsA)
- Severity-specific cases of psoriatic arthritis (PsA)

#### KOL Views

We interview KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential novel treatments by identifying the overall scenario of the indications.

#### Key questions answered

- What are the major factors that will drive the change in the patient population in psoriatic arthritis (PsA) during the forecast period (2019-2032)?
- What are the key findings pertaining to psoriatic arthritis (PsA) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of patients with psoriatic arthritis (PsA) across the 7MM during the forecast period (2019-2032)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
- What are the disease risk, burdens, and unmet needs of psoriatic arthritis (PsA)?
- What are the currently available treatments for psoriatic arthritis (PsA)?

#### Reasons to buy

Psoriatic Arthritis (PsA) epidemiology report will allow the user to:

- Develop business strategies by understanding the trends shaping and driving the global psoriatic arthritis (PsA) market
- Quantify patient populations in the global psoriatic arthritis (PsA) market to improve product design, pricing, and launch plans
- Understand the magnitude of psoriatic arthritis (PsA) population by its prevalent cases
- Understand the magnitude of psoriatic arthritis (PsA) population by its diagnosed cases
- Understand the magnitude of psoriatic arthritis (PsA) population by its age-specific cases
- Understand the magnitude of psoriatic arthritis (PsA) population by its gender-specific cases of psoriatic arthritis (PsA)
- Understand the magnitude of psoriatic arthritis (PsA) population by its severity-specific cases of psoriatic arthritis (PsA)
- Psoriatic arthritis (PsA) epidemiology report and model were written and developed by Masters and PhD level epidemiologists
- Psoriatic arthritis (PsA) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

?

#### Key Assessments

- Patient segmentation
- Disease risk and burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population

#### Geographies Covered

- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan

Study Period: 2019-2032

#### Table of Contents:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1. Key Insights
2. Report Introduction
3. Psoriatic Arthritis Market Overview at a Glance
  - 3.1. Market Share (%) Distribution of PsA in 2019
  - 3.2. Market Share (%) Distribution of PsA in 2032
4. Executive Summary of Psoriatic Arthritis
5. Disease Background and Overview
  - 5.1. Introduction
  - 5.2. Clinical Manifestations
  - 5.3. Classification
  - 5.4. Risk Factors
  - 5.5. Pathogenesis
  - 5.6. Diagnosis
  - 5.7. Differential Diagnosis
  - 5.8. Treatment and Management
    - 5.8.1. ACR/NPF Recommendations for PsA
    - 5.8.2. Summary of differences in recommendations
    - 5.8.3. EULAR Recommendations
6. Epidemiology and Patient Population
  - 6.1. Key Findings
  - 6.2. Total Prevalence of PsA in the 7MM
  - 6.3. Assumption and Rationale
  - 6.4. The United States
    - 6.4.1. Prevalent cases of PsA in the United States
    - 6.4.2. Diagnosed Cases of PsA in the United States
    - 6.4.3. Gender-specific Cases of PsA in the United States
    - 6.4.4. Age-specific Cases of PsA in the United States
    - 6.4.5. Severity-specific Cases of PsA in the United States
  - 6.5. EU5
    - 6.5.1. Total Prevalent Cases of PsA in the EU5
    - 6.5.2. Germany
      - 6.5.2.1. Diagnosed Cases of PsA in Germany
      - 6.5.2.2. Gender-specific Cases of PsA in Germany
      - 6.5.2.3. Age-specific Cases of PsA in Germany
      - 6.5.2.4. Severity-specific Cases of PsA in Germany
    - 6.5.3. France
      - 6.5.3.1. Diagnosed Cases of PsA in France
      - 6.5.3.2. Gender-specific Cases of PsA in France
      - 6.5.3.3. Age-specific Cases of PsA in France
      - 6.5.3.4. Severity-specific Cases of PsA in France
    - 6.5.4. Italy
      - 6.5.4.1. Diagnosed Cases of PsA in Italy
      - 6.5.4.2. Gender-specific Cases of PsA in Italy
      - 6.5.4.3. Age-specific Cases of PsA in Italy
      - 6.5.4.4. Severity-specific Cases of PsA in Italy
    - 6.5.5. Spain
      - 6.5.5.1. Diagnosed Cases of PsA in Spain

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.5.5.2. Gender-specific Cases of PsA in Spain
- 6.5.5.3. Age-specific Cases of PsA in Spain
- 6.5.5.4. Severity-specific Cases of PsA in Spain
- 6.5.6. The United Kingdom
  - 6.5.6.1. Diagnosed Cases of PsA in the UK
  - 6.5.6.2. Gender-specific Cases of PsA in the UK
  - 6.5.6.3. Age-specific Cases of PsA in the UK
  - 6.5.6.4. Severity-specific Cases of PsA in the UK
- 6.6. Japan
  - 6.6.1. Prevalent cases of PsA in Japan
  - 6.6.2. Diagnosed Cases of PsA in Japan
  - 6.6.3. Gender-specific Cases of PsA in Japan
  - 6.6.4. Age-specific Cases of PsA in Japan
  - 6.6.5. Severity-specific Cases of PsA in Japan
- 7. Patient Journey of Psoriatic Arthritis
- 8. SWOT Analysis
- 9. KOL Views
- 10. Unmet Needs
- 11. Market Access
- 12. Acronyms and Abbreviations
- 13. Appendix
  - 13.1. Bibliography
  - 13.2. Report Methodology
- 14. DelveInsight Capabilities
- 15. Disclaimer
- 16. About DelveInsight

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Psoriatic Arthritis - Epidemiology Forecast - 2032

Market Report | 2022-09-01 | 141 pages | DelveInsight

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User Price	\$4750.00
	Site License Price	\$9500.00
	Enterprise Price	\$14250.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-06"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com